ELVN

Enliven Therapeutics, Inc.
CAPPED RATING

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc. (ELVN) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.5 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -25.7
EV / EBITDA -21.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -11.6%
Price Return 12M 190.4%
Catalyst Signal 0.00
Market Cap $3.8B
TTM Revenue N/A
Price / Sales N/A
ROE -16.8%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D (1.5) C+ (2.7) C+ (2.6) C+ (2.6) C (2.4)
2026-11-04 C+ (2.5) D (1.4) C+ (2.7) C+ (2.8) C+ (2.7) C (2.4)
2026-10-28 C+ (2.5) D (1.4) C+ (2.7) C+ (2.8) C+ (2.7) C (2.4)
2026-10-21 C+ (2.5) D (1.4) C+ (2.8) C+ (2.7) C+ (2.6) C (2.4)
2026-10-14 C+ (2.5) D (1.4) C+ (2.8) B- (2.9) C+ (2.6) C (2.4)
Page 1 of 3